Pharmaceutical POOL
Dr. Per FALK
Novo Nordisk Names Clinical Research Head for North America Novo Nordisk, a global healthcare company focusing on diabetes care, has appointed Per Falk, M.D., Ph.D., as VP for clinical, medical, and regulatory affairs for North America. Dr. Falk leads clinical research and medical affairs in endocrinology and biopharmaceuticals, as well as regulatory affairs and medical communications. Dr. Falk joined Novo Nordisk in 2002 as a VP to establish the experimental medicine unit in Denmark, and he later moved to Tokyo, where he was responsible for drug development and market authorization of Novo Nordisk’s medical entities in Japan and Australia. In 2008, Dr. Falk transitioned to the United States as the associate VP of clinical development and medical affairs, diabetes and metabolism. Dr. Falk earned an M.D. and a Ph.D. from the University of Gothenberg in Sweden. Biotechnology POOL Dr. Sandra HORNING Genentech Selects Head of Hematology/Oncology Development Genentech, a wholly owned member of the Roche Group, has named Sandra Horning, M.D., to senior VP, global head, clinical development hematology/oncology. Dr. Horning serves as a member of Genentech’s development senior staff and is responsible for leading the medical and scientific strategies for the global clinical development portfolio in oncology. She leads the disease biology leadership team (DBLT) for oncology/hematology and manages Genentech’s team of oncology clinical scientists. She joins Genentech after more than 25 years as a practicing oncologist, investigator, and professor at Stanford University, where she leads the lymphoma disease management group. Dr. Horning earned her medical degree at the University of Iowa, trained in internal medicine at the University of Rochester, and completed medical oncology fellowship training at Stanford University. Ruhi KHAN Acorda Names Business Development VP Acorda Therapeutics has promoted Ruhi Khan to VP, business development, from executive director, business development. Ms. Khan holds an MBA from the Wharton School of the University of Pennsylvania. Acorda is developing therapies for spinal cord injury, multiple sclerosis, and related nervous system disorders. Biopharmaceutical POOL Dr. Jonathan LEFF Halozyme Appoints Medical Chief Halozyme Therapeutics, a biopharmaceutical company developing products targeting the extracellular matrix, has named Jonathan Leff, M.D., VP and chief medical officer. Dr. Leff was previously VP and global head of inflammation clinical development at Roche. He received an M.D. from the University of Pennsylvania and is board certified in internal medicine, pulmonary medicine, and critical care medicine. Craig PHILLIPS Cephalon Names Oncology VP Cephalon has promoted Craig Phillips to VP and general manager of the oncology business unit, with responsibility for managing all aspects of the U.S. oncology business, including sales, marketing, and medical affairs. Mr. Phillips joined Cephalon in 2007 as senior group director of sales, national accounts. Specialty POOL Dr. Nathaniel BROWN Presidio Names Clinical Development VP Presidio Pharmaceuticals has named Nathaniel Brown, M.D., senior VP of clinical development. Presidio is a specialty pharmaceutical company focused on the discovery, in-licensing, development, and commercialization of novel therapeutics for viral infections. Dr. Brown was previously executive VP of clinical development and chief medical officer at Idenix Pharmaceuticals. He received an M.D. from Georgetown University School of Medicine and completed clinical specialty training and postdoctoral research at the New York Hospital-Cornell Medical Center and Yale University School of Medicine. Emerging POOL Thomas DEZAO Pharma Marketing Veteran Joins ChemGenex as Commercial Chief ChemGenex Pharmaceuticals, a pharmaceutical company using genomics to develop personalized oncology medicines, has named Thomas DeZao senior VP and chief commercial officer. Mr. DeZao is leading the company’s commercial efforts for the U.S. launch of omacetaxine, which is in Phase II/III clinical trials for chronic myeloid leukemia. Before joining ChemGenex, Mr. DeZao spent six years at Genitope. Agency POOL Joseph CONWELL MedThink Communications Expands Creative Services Leadership MedThink Communications has hired Joseph Conwell as senior VP, executive creative director. Mr. Conwell joins MedThink from Euro RSCG Life/MetaMax, where he served as VP and associate creative director. He received a master’s in journalism from the University of Missouri. Gloria GIBBONS Donna TUTHS Ogilvy Healthworld Selects Joint CEOs Gloria Gibbons, president of Ogilvy Healthworld EAME, and Donna Tuths, president of Ogilvy Healthworld North America, have been appointed joint worldwide CEOs of Ogilvy Healthworld, a global healthcare communications network and WPP company. In their new roles, Ms. Gibbons and Ms. Tuths are working closely to manage the growing globalization of healthcare marketing across geographies in the Ogilvy Healthworld portfolio. Marcia GODDARD Jennifer MULVANEY Torre Lazur Healthcare Group Announces Promotions The Torre Lazur Healthcare Group (TLHG) has promoted two Torre Lazur McCann (TLM) executives to creative management roles. Marcia Goddard has been promoted to executive VP, creative director for TLM, and Jennifer Mulvaney has been promoted to executive VP, executive creative director/integration for TLHG. Previously, Ms. Goddard and Ms. Mulvaney were senior VP, co-creative directors for TLM. TLHG is comprised of several independent and integrated divisions, including TLM and echo Torre Lazur, both full-service professional healthcare agencies; Torre Lazur Active Ingredient, specializing in interactive and video; and Torre Lazur Managed Markets. Amy JUEL Darcy ROSS Topin Strengthens Management Staff Topin & Associates, a full-service healthcare marketing communications agency, has named Amy Juel as senior project manager. Ms. Juel has more than a decade of experience leading teams in planning and executing advertising and branding campaigns, most recently as an account director at VSA Partners. Darcy Ross has been named senior manager of digital communications. Before joining Topin, Ms. Ross worked as an interactive producer for Goble & Associates. Consulting POOL Susan Sisskind DUNNE Chris MCKEIL Huron Expands Life Sciences Team Susan Sisskind Dunne has joined Huron Consulting Group as a director focused on government price reporting matters. Formerly with KPMG and Morgan Lewis & Bockius, Ms. Dunne is in Huron’s Washington, D.C., office. Huron’s other director appointee, Chris McKeil, is based in Huron’s New York office. Mr. McKeil comes to Huron from Accenture. George QUESNELLE PinneyAssociates Adds Expert George Quesnelle has joined life-sciences consultancy firm PinneyAssociates as senior strategic advisor. Mr. Quesnelle recently retired as president of GlaxoSmithKline Consumer Healthcare North America. Dr. Michael SALGALLER Holly SCOTT Biologics Consulting Makes Appointments Biologics Consulting Group, a regulatory affairs consulting firm, has appointed Michael Salgaller, Ph.D., president and chief operating officer. Dr. Salgaller was chief operating officer for Calibrant Biosystems. He has a Ph.D. in pathology from The Ohio State University and an M.S. in immunology from the University of Dayton. In addition, Holly Scott has joined Biologics Consulting Group as senior consultant. Ms. Scott brings almost two decades of FDA experience to the group, most recently as a field investigator with the FDA, Florida District. Taryn Fritz WALPOLE Former FDA Staffer Joins Greenleaf Health Taryn Fritz Walpole, former deputy chief of staff at the FDA, has joined Greenleaf Health as VP, corporate affairs, providing consulting services and managing the firm’s Washington, D.C., office. Greenleaf Health is a full-service regulatory consulting firm. CRO POOL Christopher BERGEN Dr. Stephen CUTLER Simon HIGGINBOTHAM Kendle Realigns Executive Leadership Global CRO Kendle has reorganized and expanded its leadership team to strengthen its competitive position and set the company for continued growth. Co-founder and Chief Operating Officer Christopher Bergen has assumed the newly created position of executive VP and chief administrative officer (CAO). The addition of a CAO role within Kendle’s executive leadership team helps the company ensure it has in place the technology and infrastructure to deliver optimal outsourcing solutions for global biopharmaceutical customers. Mr. Bergen served as president and chief operating officer since Kendle’s founding in June 1981 until April 2008 and as chief operating officer after that. He received an MBA from the Wharton School of the University of Pennsylvania and has completed the Harvard Business School Owner/President Management Program. In conjunction with Mr. Bergen’s appointment, Kendle has named Stephen Cutler, Ph.D., senior VP and chief operating officer, providing global leadership for the company’s worldwide late-stage operations. Dr. Cutler joins Kendle following 14 years with Quintiles, where he most recently was senior VP, global project management. He holds a doctorate in philosophy from the University of Sydney and an MBA from the University of Birmingham in the United Kingdom. In other moves, Simon Higginbotham is assuming the title of senior VP and chief marketing officer. The addition of marketing chief to Mr. Higginbotham’s leadership responsibilities for the company’s early-stage business reflects Kendle’s increasing focus on strategic customer relationships. Dr. Jim LAVEGLIA Dr. Tina ROGERS MPI Research Makes Leadership Changes MPI Research, a provider of preclinical and early clinical research and development services, has promoted Jim Laveglia, Ph.D., to executive VP focused on business development. Dr. Laveglia has served as MPI’s director of research since 1997. He received a Ph.D. from Iowa State University. Tina Rogers, Ph.D., formerly MPI’s discovery center director, has assumed Dr. Laveglia’s former role as director of research. Dr. Rogers received a Ph.D. in molecular and cellular biology and pathobiology from the Medical University of South Carolina, and he completed postdoctoral fellowships at Harvard Medical School and Tufts University School of Medicine. She is a Diplomate of the American Board of Toxicology (DABT), currently serves on the MBA advisory board at the Auburn University School of Business, and is a member of the Gerson Lehman Group Healthcare Council. Service POOL Maggie HELMIG inVentiv Selling Solutions Appoints Business Development VP inVentiv Selling Solutions, a division of inVentiv Health and a provider of outsourced sales teams to the pharmaceutical industry, has named Maggie Helmig as senior VP, business development. Ms. Helmig was previously president of Eden Communications. Laura Marsh LYNNER Publicis Strategic Solutions Selects Chief Operating Chief Publicis Strategic Solutions Group, a division of Publicis Healthcare Communications Group and a provider of multichannel message delivery solutions, has named Laura Marsh Lynner chief operating officer. Previously, Ms. Lynner was executive VP and managing director of Scientific Voice. Ms. Lynner is responsible for the day-to-day operations of the recently formed Strategic Solutions Group, which aligns Publicis’ key message delivery companies — Publicis Selling Solutions, Scientific Voice, Pharmagistics, and Arista Marketing Associates. Dr. Liza SOLOMON Abt Associates Taps AIDS Expert as Principal Associate Liza Solomon, Dr.P.H., former director of the Maryland State AIDS Administration, has joined Abt Associates as a principal associate in its domestic health division. Abt Associates applies scientific research, technical assistance, survey, and consulting expertise to a wide range of social, economic, and health policy issues. Before joining Abt, Dr. Solomon was deputy director of the Alliance for Microbicide Development. She earned a Dr.P.H. and an M.H.S. from the Johns Hopkins School of Hygiene and Public Health. Technology POOL Dr. Jeffrey DAVIDSON Octagon Research Appoints Clinical Statistics Director Octagon Research Solutions, a provider of software and services, has appointed Jeffrey Davidson, Ph.D., to senior director, clinical statistics. He is responsible for overseeing all statistical activities and staff, as well as providing strategic direction and leadership for all statistical functions. Dr. Davidson was most recently senior VP, statistical consulting, at a global contract research organization. He holds a Special Education M.Ed. from the College of New Jersey and a METER (Measurements, Evaluations, and Techniques of Experimental Research) Ph.D. from the University of Pennsylvania. Tammy MILLER ERT Appoints Project Management VP Tammy Miller has joined ERT as VP of project management, with responsibility for the global implementation and delivery of ERT’s project assurance methodology. ERT is a provider of centralized ECG and e-clinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries. Ms. Miller has 24 years of experience in the healthcare industry, most recently working as group director for CNS at Quintiles. She received an MBA in global management from the University of Phoenix. F Send your personnel announcements to [email protected]. Biotechnology POOL Dr. Diana HAUSMAN Oncothyreon Names Clinical Development VP Oncothyreon, a biotechnology company specializing in the development of therapeutics for cancer, has appointed Diana Hausman, M.D., VP, clinical development. Dr. Hausman is responsible for planning and implementing the clinical development program for the company’s oncology product candidates. She was most recently senior director of clinical research at Zymogenetics. Biopharmaceutical POOL Gregg ALTON Gilead Announces Senior Management Promotion Gilead Sciences, a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, has promoted Gregg Alton to executive VP, corporate and medical affairs, from senior VP and general counsel. Mr. Alton also has assumed the additional responsibility of managing Gilead’s global medical affairs activities and personnel. He received a J.D. from Stanford University. Dr. Jason FEWELL EGEN Promotes R&D VP EGEN, a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, has promoted Jason Fewell, Ph.D., to VP of preclinical research and development. Dr. Fewell has served as EGEN’s director of biology and pharmacology since 2003. He received a Ph.D. in biological science from Florida State University and was a postdoctoral fellow at Cincinnati’s Children Hospital. Dr. Mark GOLDSMITH Constellation Pharmaceuticals Selects CEO Constellation Pharmaceuticals, a biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, has appointed Mark Goldsmith, M.D., Ph.D., as CEO. Dr. Goldsmith has held senior positions in academia and the biotechnology industry, including co-founder and CEO of Cogentus Pharmaceuticals. Until recently he was senior executive-in-residence at Prospect Venture Partners. He received an M.D. and a Ph.D. in microbiology and immunology from the University of California, San Francisco. Dr. Stephen MURRAY Omeros Names Clinical Development Head Omeros, a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing products for inflammation and disorders of the central nervous system, has appointed Stephen Murray, M.D., Ph.D., VP of clinical development, responsible for overseeing clinical trial strategies and protocols. Dr. Murray is leading the ongoing clinical studies for Omeros’ PharmacoSurgery product candidates. Dr. Murray was previously chief medical officer at Memory Pharmaceuticals. He received an M.D. and a Ph.D. in molecular and cellular biology from the Medical University of South Carolina and completed his training in psychiatry at the University of California, San Francisco. Specialty POOL Dr. Moh
mmad AZAB SuperGen Appoints Medical Chief Oncology specialty company SuperGen has appointed Mohammad Azab, M.D., chief medical officer, with oversight of SuperGen’s clinical development strategy, clinical operations, regulatory affairs, quality, and safety departments. His responsibilities include the design and execution of clinical trials, including the recently commenced Phase I study of the PIM kinase inhibitor, SGI-1776. Most recently, Dr. Azab was president and CEO of Intradigm. He received a medical degree from Cairo University and an MBA with distinction from the Richard Ivey School of Business, University of Western Ontario. Dr. Azab received postgraduate training and degrees in oncology research and statistics from the University of Paris-Sud and the University of Pierre and Marie Curie in France. Dr. T. Scott JOHNSON The Medicines Company Names New Business VP T. Scott Johnson, M.D., has joined The Medicines Company on a full-time basis as VP, new business ventures and chief medical advisor, and he has resigned as a director of the firm. Dr. Johnson is working to evaluate new product acquisition opportunities and provide medical advice on both marketed and development products in the company’s portfolio. Previously, Dr. Johnson was a partner at Gilliam Capital, an investment management company that he founded in June 2007. He had been a director of The Medicines Company since its inception in September 1996. He received an M.D. from the University of Alabama. The Medicines Company specializes in advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Generic POOL Heather BRESCH Rajiv MALIK Timothy SAWYER Mylan Enhances Management Team Global genetics firm Mylan has made two promotions and one addition to its executive management team. Heather Bresch, a 17-year Mylan veteran, has been promoted to president from chief operating officer. In this expanded role, Ms. Bresch has assumed additional leadership responsibilities related to the day-to-day operations of the company. Rajiv Malik has been promoted to chief operating officer from head of Mylan’s global technical operations, where he oversaw R&D and manufacturing; supply chain and sourcing; and quality and regulatory affairs. In addition to these responsibilities, Mr. Malik now oversees the company’s generic biologics efforts as well as those initiatives related to emerging markets. Timothy Sawyer has joined Mylan as senior VP of strategic corporate development. Mr. Sawyer works closely with the other senior management members to help lead the company’s global strategic development activities. Mr. Sawyer has 16 years of experience in the generic pharmaceutical industry, most recently as executive VP, global generic sales and marketing, for Barr Laboratories. Agency POOL Mykola BILOKONSKY Meredith BISCHOFF Matt CASH Ryan FAZULAK Lynn LONGBRAKE Shannon OWEN Jared WEINSTOCK Blue Diesel Makes Staff Changes Interactive marketing agency Blue Diesel, an inVentiv Health company, has announced a number of appointments at its locations in Newtown, Pa., and Columbus, Ohio. Mykola Bilokonsky has been named multimedia developer in the Columbus office. Mr. Bilokonsky previously served as media producer for The Ohio State University. Also in Columbus, Meredith Bischoff has been appointed account manager. Ms. Bischoff was most recently client services manager for Resource Interactive. Matt Cash has joined the Columbus office as senior interactive designer. Mr. Cash previously worked for Fox Sports Interactive as interactive design lead. Ryan Fazulak has been named interactive designer in the Columbus office. Previously, Mr. Fazulak was designer at Bridge Worldwide. Also in Columbus, Lynn Longbrake has been appointed creative director. Ms. Longbrake was most recently associate creative director for Resource Interactive. Shannon Owen has been named senior art director in the Columbus office. Ms. Owen previously served as director of account services and operations for Terralever. Jared Weinstock has joined the Newtown office as multimedia developer. Mr. Weinstock previously worked for Hall Media Productions as multimedia designer. Service POOL Glenn REICIN Skyline Ventures Expands Investment Team Skyline Ventures, a venture capital firm that focuses on medical device and biopharmaceutical investing, has promoted Glenn Reicin to managing director. Mr. Reicin was previously a venture partner at Skyline, a position he has held since October 2008. He received an MBA from Harvard Business School. Send your personnel announcements to [email protected]. F
